January 2025 FDA New Drug Approvals: Datroway (datopotamab deruxtecan-dlnk) is a TROP2-directed antibody and topoisomerase inhibitor conjugate used for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer. Join our vibrant community on LinkedIn for the latest updates on publishing, research, and pharmaceutical webinars. Don't miss out on exclusive insights and opportunities to elevate your career. Follow us now and be part of the SPSR journey! https://www.linkedin.com/company/spsr2010